GRI Bio (GRI) investor relations material

Executive summary

• Clinical-stage biopharma focused on therapies for inflammatory, fibrotic, and autoimmune disorders, with lead candidate GRI-0621 targeting idiopathic pulmonary fibrosis (IPF).

• GRI-0621 received FDA Orphan Drug Designation in June 2026 for IPF, providing potential market exclusivity and development incentives.

• Phase 2a trial for GRI-0621 met primary safety and tolerability endpoints, with secondary biomarker and pulmonary function improvements observed.

• Company is evaluating next clinical steps for GRI-0621 and preparing for further regulatory engagement.

Financial highlights

• Net loss for Q2 2026 was $1.6 million, compared to $2.9 million in Q2 2025; six-month net loss was $3.6 million, down from $5.9 million year-over-year.

• Operating expenses for Q2 2026 were $1.6 million, with R&D at $0.4 million and G&A at $1.2 million.

• Cash and cash equivalents totaled $10.9 million as of June 30, 2026, up from $8.2 million at year-end 2025.

• Accumulated deficit reached $55.3 million as of June 30, 2026.

Outlook and guidance

• Existing cash is expected to fund operations through Q2 2027, assuming only preliminary work on new clinical studies.

• Additional capital will be required to complete further clinical trials for GRI-0621.

• Company intends to seek further funding via equity, debt, or partnerships, but there is substantial doubt about ability to continue as a going concern without new capital.